#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem-Cell-Derived Neurons."
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/conso
# --------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
 DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
 DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
 DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
 DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
 DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
# DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns"
 DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
 DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
# DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
 DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
 DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
# DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
 DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
 DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "30935091"}

SET Evidence = "In mouse cortical neuron cultures, it was shown that inhibiting HDAC6 through
genetic and pharmacological methods led to increased survival and neuronal regeneration in the
setting of oxidative stress [24]."
#in case of oxidative stress
SET Species = "10090"
SET MeSHAnatomy = "Neocortex"
p(HGNC:HDAC6) -> path(MESH:"Nerve Degeneration")

SET Evidence = "In an another study using mouse cortical neuron cultures, it was shown
that axonal degeneration from kainic acid was accompanied by significant decrease in alpha-tubulin
acetylation [25]. Treatment with an HDAC inhibitor resulted in higher levels of alpha-tubulin acetylation,
as expected, but it also protected the neurons from kainic acid-induced axonal degeneration [25]."
a(CHEBI:"kainic acid") -> path(DOID:"axonal neuropathy")
path(DOID:"axonal neuropathy") -| p(INTERPRO:"Alpha tubulin",pmod(Ac))
p(HGNC:HDAC6) -| p(INTERPRO:"Alpha tubulin",pmod(Ac))
p(HGNC:HDAC6) -> act(a(CHEBI:"kainic acid"))
p(HGNC:HDAC6) -> path(DOID:"axonal neuropathy")
UNSET MeSHAnatomy
UNSET Species

SET Evidence = "A number of ALS-associated proteins have been found
to regulate the activity of HDAC6, specifically the proteins Fused in Sarcoma/Translocated in Sarcoma
(FUS/TLS) and TAR DNA binding protein-43 (TDP-43) [27–30]."
p(HGNC:FUS) -- path(DOID:"amyotrophic lateral sclerosis")
p(HGNC:TARDBP) -- path(DOID:"amyotrophic lateral sclerosis")
p(HGNC:FUS) reg act(p(HGNC:HDAC6))
p(HGNC:TARDBP) reg act(p(HGNC:HDAC6))

SET Evidence = "Some of the early studies suggested
that HDAC6 may have a protective effect in ALS, and it was found SOD1G93A mice has lower levels of
HDAC6 expression at disease onset which became very low at the later stages [31]."
p(HGNC:HDAC6) -| path(DOID:"amyotrophic lateral sclerosis")
SET Species = "10090"
p(HGNC:SOD1,var("p.Gly93Ala")) -| p(HGNC:HDAC6)
UNSET Species

SET Evidence = "In cultured cells,
it was initially shown that HDAC6 knockdown led to increased aggregation of mutant SOD1 and that
HDAC6 may facilitate degradation of aggregation-prone proteins in the cytoplasm [32,33]."
p(HGNC:HDAC6) -> p(HGNC:SOD1,var("p.Gly93Ala"),pmod(CONSO:"protein aggregates"))
p(HGNC:SOD1,var("p.Gly93Ala"),pmod(CONSO:"protein aggregates"),loc(GO:cytoplasm)) -> deg(p(HGNC:SOD1,var("p.Gly93Ala"),pmod(CONSO:"protein aggregates")))
p(HGNC:HDAC6) -> deg(p(HGNC:SOD1,var("p.Gly93Ala"),pmod(CONSO:"protein aggregates")))

SET Evidence = "However,
in the SOD1G93A mouse model of ALS, deletion of the HDAC6 gene led to a significant decrease
in progression of disease and resulted in prolonged survival, which was accompanied by increased
alpha-tubulin acetylation [34]."
SET Species = "10090"
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:HDAC6) -| bp(MESH:"Cell Survival")
bp(MESH:"Cell Survival") -> p(INTERPRO:"Alpha tubulin",pmod(Ac))
p(HGNC:HDAC6) -| p(INTERPRO:"Alpha tubulin",pmod(Ac))
UNSET MeSHDisease
UNSET Species

SET Evidence = "In an amyloid precursor protein/presenilin 1 (APP/PS1) mouse model, treatment with the HDAC6
inhibitor ACY-738 resulted in improvement of axonal transport rates, decrease in phosphorylation
of tau and increase in alpha-tubulin acetylation, accompanied by improvement in amyloid pathology
as well as contextual learning and memory [23]."
#APP/PS1 model
#57381425 - ACY-738
SET Species = "10090"
a(PUBCHEM:57381425) -| p(HGNC:HDAC6)
a(PUBCHEM:57381425) -> bp(GO:"axonal transport")
a(PUBCHEM:57381425) -| p(HGNC:MAPT,pmod(Ph))
a(PUBCHEM:57381425) -> p(INTERPRO:"Alpha tubulin",pmod(Ac))
a(PUBCHEM:57381425) -| path(MESH:"Amyloid Neuropathies")
a(PUBCHEM:57381425) -> bp(GO:"learning or memory")
UNSET Species

#neuritic tau beads?
SET Evidence = "Studies in mice and rodent neurons showed that
genetic or pharmacological reduction in HDAC6 activity can also decrease tau mislocalization and
suppress the pathogenic formation of neuritic tau beads [37]."
SET Species = {"10116","10090"}
act(p(HGNC:HDAC6)) -> act(p(HGNC:MAPT),ma(MESH:"Protein Transport"))
act(p(HGNC:HDAC6)) -> p(CONSO:"Tau fibrils")
UNSET Species

SET Evidence = "When APPPS1-21 mice, which show
memory impairment, amyloid pathology and low levels of alpha-tubulin acetylation, were crossed with
Hdac6 knockout mice, it was found that the reduction in HDAC6 led to improvement in memory
function, accompanied by robust increases in acetylated alpha-tubulin [38]."
#APP/PS1 model
SET Species = "10090"
p(HGNC:HDAC6) -| bp(GO:"learning or memory")
p(HGNC:HDAC6) -| p(INTERPRO:"Alpha tubulin",pmod(Ac))
UNSET Species

SET Evidence = "In a study using rTg4510
mouse model of tau deposition, it was shown that treatment with the HDAC6 inhibitor Tubastatin
A resulted in improved memory function as well as decreased levels of tau [39]."
#rTg4510
#49850262 - Tubastatin A
SET Species = "10090"
a(PUBCHEM:49850262) -| p(HGNC:HDAC6)
a(PUBCHEM:49850262) -> bp(GO:"learning or memory")
a(PUBCHEM:49850262) -| p(HGNC:MAPT)
UNSET Species

SET Evidence = "In another study of an Alzheimer’s disease mouse model treatment with ACY-1215 and Tubastatin A,
both led to improvement in the behavioral assays as well as changes in amyloidlevels, decrease in
phosphorylation of tau and increase in alpha-tubulin acetylation [40]."
#53340666 - ACY-1215
SET Species = "10090"
SET MeSHDisease = "Alzheimer Disease"
a(PUBCHEM:53340666) -- p(MESH:"Amyloidogenic Proteins")
a(PUBCHEM:49850262) -- p(MESH:"Amyloidogenic Proteins")
a(PUBCHEM:53340666) -| p(HGNC:MAPT,pmod(Ph))
a(PUBCHEM:49850262) -| p(HGNC:MAPT,pmod(Ph))
a(PUBCHEM:53340666) -> p(INTERPRO:"Alpha tubulin",pmod(Ac))
a(PUBCHEM:49850262) -> p(INTERPRO:"Alpha tubulin",pmod(Ac))
UNSET MeSHDisease
UNSET Species

#in APP(swe) and tauP301L mutant mouse models of Alzheimer's
SET Species = "10090"
SET MeSHDisease = "Alzheimer Disease"

SET Evidence = "Pharmacological inhibition of HDAC6 in these mice led to improvement in learning and memory tasks,
accompanied by increased alpha-tubulin acetylation in the brain as well as decreased tau S396 and S404
phosphorylation [42]."
p(HGNC:HDAC6) -| bp(GO:"learning or memory")
p(HGNC:HDAC6) -| p(INTERPRO:"Alpha tubulin",pmod(Ac))
p(HGNC:HDAC6) -> p(HGNC:MAPT,pmod(Ph,Ser,369))
p(HGNC:HDAC6) -> p(HGNC:MAPT,pmod(Ph,Ser,404))

SET Evidence = "Experiments in SH-SY5Y and Neuro2a cell lines showed that pharmacological
HDAC6 inhibition resulted in reduced phosphorylation and aggregation of tau and increased Hsp90
acetylation, accompanied by increased phosphorylation by Akt of the S9 residue on glycogen synthase
kinase beta (GSK3 beta) [42]."
SET CellLine = {"SH-SY5Y","Neuro-2a cell"}
p(HGNC:HDAC6) -> p(HGNC:MAPT,pmod(Ph))
p(HGNC:HDAC6) -> p(CONSO:"Tau aggregates")
p(HGNC:HDAC6) -> p(HGNCGENEFAMILY:"Heat shock 90kDa proteins",pmod(Ac))
p(HGNC:HDAC6) -> act(p(HGNC:AKT2))
p(HGNC:AKT2) -> p(HGNC:GSK3B,pmod(Ph,Ser,9))
p(HGNC:HDAC6) -> p(HGNC:GSK3B,pmod(Ph,Ser,9))
UNSET CellLine

UNSET MeSHDisease
UNSET Species

#HSPB1 model of Charcot-Marie-Tooth disease
SET Species = "10090"
SET MeSHDisease = "Charcot-Marie-Tooth Disease"

SET Evidence = "Cultured DRG neurons from a mutant HSPB1 mouse model of
Charcot-Marie-Tooth disease showed deficits in axonal transport and this deficit was rescued by
the HDAC6 inhibitors ACY-738 and ACY-775 [46]."
#57382288 - ACY-775
a(PUBCHEM:57381425) pos bp(GO:"axonal transport")
a(PUBCHEM:57382288) pos bp(GO:"axonal transport")
path(DOID:"Charcot-Marie-Tooth disease") neg bp(GO:"axonal transport")

SET Evidence = "Another mouse model of Charcot-Marie-Tooth
disease, based on dominant mutations in glycyl-tRNA synthetase, showed that the mice have aberrant
axonal transport and this is accompanied by decreased alpha-tubulin acetylation [47]."
path(DOID:"Charcot-Marie-Tooth disease") -> p(HGNC:GARS,var("?"))
p(HGNC:GARS,var("?")) neg bp(GO:"axonal transport")
p(HGNC:GARS,var("?")) -| p(INTERPRO:"Alpha tubulin",pmod(Ac))

SET Evidence = "Treatment with
the HDAC6 inhibitor Tubastatin A led to increased alpha-tubulin acetylation, ameliorated the deficits in
axonal transport and improved the motor functioning in the mutant mice [47]."
a(PUBCHEM:49850262) -> p(INTERPRO:"Alpha tubulin",pmod(Ac))
a(PUBCHEM:49850262) pos bp(GO:"axonal transport")
a(PUBCHEM:49850262) -> bp(GO:"motor behavior")

SET Evidence = "In a study of cortical
neurons from a Rett syndrome MECP2T158A mouse model and of patient fibroblasts, it was found that
the cortical neurons of the MECP2-deficient mice and the patient fibroblasts had increased levels of
HDAC6 protein expression and reduced levels of acetylated alpha-tubulin and treatment with Tubastatin
A resulted in increased levels of acetylated alpha-tubulin [48]."
#MECP2T158A ,ousel model
SET MeSHAnatomy = {"Fibroblasts","Neocortex"}
path(DOID:"Rett syndrome") -> p(HGNC:HDAC6)
path(DOID:"Rett syndrome") -| p(INTERPRO:"Alpha tubulin",pmod(Ac))
UNSET MeSHAnatomy

UNSET MeSHDisease
UNSET Species

#in oligodendrocytes
SET Cell = "oligodendrocyte"

SET Evidence = "Cultured rat oligodendrocytes were shown to express HDAC6 and
inhibition of HDAC6 by Tubastatin A resulted in decreased microtubule binding activity of tau [51]."
SET Species = "10116"
p(HGNC:HDAC6) -> act(p(HGNC:MAPT),ma(GO:"microtubule binding"))
a(PUBCHEM:49850262) -| act(p(HGNC:MAPT),ma(GO:"microtubule binding"))
UNSET Species

SET Evidence = "It was shown that HDAC6 inhibition led to increased acetylation of tau in the oligodendrocytes,
which in turn reduced its turnover rate [51]."
p(HGNC:HDAC6) -| p(HGNC:MAPT,pmod(Ac))
p(HGNC:HDAC6) -> p(HGNC:MAPT)
p(HGNC:MAPT,pmod(Ac)) -| p(HGNC:MAPT)

SET Evidence = "Furthermore, proteasomal inhibition led to the
accumulation of acetylated tau and HDAC6 in protein aggregates, which was altered by Tubastatin A
or RNAi-mediated downregulation of HDAC6 [52]."
complex(GO:"proteasome complex") -| p(HGNC:MAPT,pmod(Ac),pmod(CONSO:"protein aggregates"))
complex(GO:"proteasome complex") -| p(HGNC:HDAC6,pmod(CONSO:"protein aggregates"))
a(PUBCHEM:49850262) -| p(HGNC:MAPT,pmod(Ac),pmod(CONSO:"protein aggregates"))
a(PUBCHEM:49850262) -| p(HGNC:HDAC6,pmod(CONSO:"protein aggregates"))

SET Evidence = "In addition, experiments in oligodendroglial cell
lines showed that HDAC6 dysregulation played a role in stress responses in these cells [52]."
p(HGNC:HDAC6) neg bp(GO:"response to oxidative stress")

UNSET Cell

SET Evidence = "Inhibition of HDAC6 by Tubastatin A upregulated heat-shock proteins HSP25 and HSP70 and led to
increased cell survival in the setting of oxidative stress [53]."
a(PUBCHEM:49850262) -> p(HGNC:HSPB1)
a(PUBCHEM:49850262) -> p(HGNCGENEFAMILY:"Heat shock 70kDa proteins")
p(HGNC:HSPB1) -| bp(MESH:"Oxidative Stress")
p(HGNCGENEFAMILY:"Heat shock 70kDa proteins") -| bp(MESH:"Oxidative Stress")
p(HGNC:HSPB1) -> bp(MESH:"Cell Survival")
p(HGNCGENEFAMILY:"Heat shock 70kDa proteins") -> bp(MESH:"Cell Survival")

#in human neuronal cells
SET Species = "9606"
SET Cell = "neuron"

SET Evidence = "Treatment with two different pharmacological inhibitors of HDAC6 led to increased acetylation of
a-tubulin and rescue of the deficits in movement of mitochondria in the axons [75]."
#in iPSc's from CMT2F and dHMN2B carrying HSPB1
SET MeSHDisease = {"Charcot-Marie-Tooth Disease","Motor Neuron Disease"}
p(HGNC:HDAC6) -| p(INTERPRO:"Alpha tubulin",pmod(Ac))
p(HGNC:HDAC6) neg bp(GO:"axonal transport of mitochondrion")
UNSET MeSHDisease

SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
SET MeSHAnatomy = "Motor Neurons"

SET Evidence = "Motor neurons differentiated from FUS3 mutant iPSC lines, as well as motor
neurons from human embryonic stem cells (hESCs) expressing mutant FUS, showed characteristic
cellular and functional findings of cytoplasmic FUS accumulation, hypoexcitability, and deficits in
axonal transport [76]."
#iPSC-derived motor neuron from ALS with FUS mutation
p(HGNC:FUS,var("?")) -> p(HGNC:FUS,loc(GO:cytoplasm))
p(HGNC:FUS,var("?")) neg bp(GO:"axonal transport")

SET Evidence = "They further showed that inhibiting HDAC6, with the HDAC6-specific inhibitors
Tubastatin A and ACY-738 or with antisense oligonucleotides, rescued the deficits in axonal transport
in those motor neurons [76]."
a(PUBCHEM:49850262) pos bp(GO:"axonal transport")
a(PUBCHEM:57381425) pos bp(GO:"axonal transport")

UNSET MeSHAnatomy
UNSET MeSHDisease

SET Evidence = "Neurons differentiated from iPSCs of Rett syndrome patients with MECP2
mutations showed a transcriptomic profile that indicated disruption in GABAergic circuits as well
a significant upregulation of HDAC6 [77].This was accompanied by decreased levels alpha-tubulin
acetylation in the MECP2 neurons, which were reversed with treatment with the HDAC6 inhibitor
ACY-1215 [77]."
#53340666 - ACY-1215
SET MeSHDisease = "Rett Syndrome"
p(HGNC:MECP2,var("?")) neg bp(GO:"synaptic transmission, GABAergic")
p(HGNC:MECP2,var("?")) -> p(HGNC:HDAC6)
p(HGNC:MECP2,var("?")) -| p(INTERPRO:"Alpha tubulin",pmod(Ac))
a(PUBCHEM:53340666) -| p(HGNC:HDAC6)
a(PUBCHEM:53340666) -> p(INTERPRO:"Alpha tubulin",pmod(Ac))
UNSET MeSHDisease

UNSET Cell
UNSET Species

SET Evidence = "The mood stabilizer valproic acid has been shown
to possess HDAC inhibitory activity [81]."
a(CHEBI:"valproic acid") -|  p(MESH:"Histone Deacetylases")

SET Evidence = "Multiple HDACi have antidepressant-like activity in
pre-clinical animal models, including sodium butyrate, suberoylanilide hydroxamic acid (SAHA),
MS-275, and Cpd-60 [82–86]."
#HDACi - HDAC inhibitor
#5311 - SAHA, 4261 - MS-275, 134164107 - Cpd-60
a(CHEBI:"sodium butyrate") -| p(HGNC:HDAC6)
a(PUBCHEM:5311) -| p(HGNC:HDAC6)
a(PUBCHEM:4261) -| p(HGNC:HDAC6)
a(PUBCHEM:134164107) -| p(HGNC:HDAC6)

SET Evidence = "In mice, the SSRI fluoxetine and the class I HDACi MS-275 reverse the
effects of chronic social defeat stress on global patterns of gene expression [8]."
SET Species = "10090"
a(PUBCHEM:4261) -| p(HGNCGENEFAMILY:"Histone deacetylases, class I")
a(CHEBI:fluoxetine) -| path(DOID:"antisocial personality disorder")
a(PUBCHEM:4261) -| path(DOID:"antisocial personality disorder")
UNSET Species

SET Evidence = "It has been shown that
the HDACi Cpd-60 modulates mood-related behaviors in mice and induces brain gene-expression
changes that overlap with lithium treatment [83]."
SET Species = "10090"
a(PUBCHEM:134164107) reg path(MESH:Affect)
SET MeSHAnatomy = "Brain"
a(PUBCHEM:134164107) reg bp(GO:"gene expression")
UNSET MeSHAnatomy
UNSET Species

SET Evidence = "Antidepressant-like behaviors were also described in rodents with loss of
function of HDAC6 [22,87]."
SET Species = "10116"
p(HGNC:HDAC6) pos path(MESH:Depression)
UNSET Species

SET Evidence = "GSK3 beta phosphorylates beta-catenin and primes it for proteasomal
degradation."
p(HGNC:GSK3B) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph))
p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph)) ->  complex(complex(GO:"proteasome complex"),p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph)))
complex(complex(GO:"proteasome complex"),p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph))) -> deg(p(HGNCGENEFAMILY:"Beta catenins"))

SET Evidence = "In this complex, GSK3 beta constitutively
phosphorylatesbeta-catenin. This phosphorylated version of beta-catenin is recognized by betarCP of the
E3 ubiquitin ligase complex and degraded by the proteasome [102]."
#complex - beta-catenin, GSK3 beta, APC, Auxin
p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph)) -> complex(complex(GO:"SCF ubiquitin ligase complex"),p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph)))
complex(complex(GO:"SCF ubiquitin ligase complex"),p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph))) -> deg(p(HGNCGENEFAMILY:"Beta catenins"))

SET Evidence = "When Wnt ligands bind to the
Frizzled/LRP receptor, Axin is recruited to the membrane, resulting in dismantling of the destruction
complex."
complex(p(HGNCGENEFAMILY:"Wnt family"),p(HGNC:LRP1)) -> p(HGNC:AXIN1)
p(HGNC:AXIN1) -| complex(p(HGNC:AXIN1),p(HGNCGENEFAMILY:"Beta catenins"),p(HGNC:GSK3B),p(HGNC:APC))

SET Evidence = "-catenin then accumulates and translocates to the nucleus, where it binds to the T-cell Factor
(TCF) transcription factors and increases transcription of target genes [102]."
#due to the destruction
p(HGNC:AXIN1) -> p(HGNCGENEFAMILY:"Beta catenins")
p(HGNCGENEFAMILY:"Beta catenins") -> tloc(p(HGNCGENEFAMILY:"Beta catenins"),fromLoc(GO:cytoplasm),toLoc(GO:nucleus))
p(HGNCGENEFAMILY:"Beta catenins",loc(GO:nucleus)) -> complex(p(HGNCGENEFAMILY:"Beta catenins"),p(HGNCGENEFAMILY:"TCF/LEF transcription factor family"))
complex(p(HGNCGENEFAMILY:"Beta catenins"),p(HGNCGENEFAMILY:"TCF/LEF transcription factor family")) -> bp(GO:"mRNA transcription")

SET Evidence = "K49 is often found mutated to arginine in anaplastic
thyroid carcinomas, resulting in increased nuclear localization of beta-catenin [105]."
path(EFO:"Thyroid Gland Undifferentiated (Anaplastic) Carcinoma") -> p(HGNCGENEFAMILY:"Beta catenins",var("p.Lys49Arg"))
p(HGNCGENEFAMILY:"Beta catenins",var("p.Lys49Arg")) -> p(HGNCGENEFAMILY:"Beta catenins",loc(GO:nucleus))

SET Evidence = "In cancer cell lines
SW480 and HCT116, K49 deacetylation was necessary for epidermal growth factor (EGF)-induced
nuclear localization ofbeta-catenin [106]."
SET CellLine = {"SW480","HCT116"}
p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac,Lys,49)) -| act(p(HGNC:EGF))
p(HGNC:EGF) -> p(HGNCGENEFAMILY:"Beta catenins",loc(GO:nucleus))
p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac,Lys,49)) -| p(HGNCGENEFAMILY:"Beta catenins",loc(GO:nucleus))
UNSET CellLine

SET Evidence = "While human NPCs had minimal Ac-K49-beta-catenin at baseline, treatment with the pan-HDACi
SAHA and another broadly selective HDACi crebinostat led to a marked increase in Ac-K49-beta-catenin
levels, without affecting overallbeta-catenin levels [103]."
a(CONSO:crebinostat) -| p(HGNC:HDAC6)
a(PUBCHEM:5311) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac,Lys,49))
a(CONSO:crebinostat) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac,Lys,49))
a(PUBCHEM:5311) cnc p(HGNCGENEFAMILY:"Beta catenins")
a(CONSO:crebinostat) cnc p(HGNCGENEFAMILY:"Beta catenins")

SET Evidence = "Class I specific HDACi MS-275 and BG-45 did
not increase Ac-K49-beta-catenin, but treatment with HDAC6i ACY- resulted in marked increase
in Ac-K49-beta-catenin."
#16773791 - BG-45,
a(PUBCHEM:4261) -| p(HGNCGENEFAMILY:"Histone deacetylases, class I")
a(PUBCHEM:4261) cnc p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac,Lys,49))
a(PUBCHEM:16773791) -| p(HGNCGENEFAMILY:"Histone deacetylases, class I")
a(PUBCHEM:16773791) cnc p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac,Lys,49))
a(PUBCHEM:53340666) -| p(HGNC:HDAC6)
a(PUBCHEM:53340666) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac,Lys,49))

SET Evidence = "Experiments were undertaken to investigate how K49 acetylation on beta-catenin
affected adjacent phosphorylation sites in the N-terminal regulatory domain — CK1alpha site S45 and
GSK3 beta sites S33/S37/T41."
p(HGNC:CSNK1A1) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph,Ser,45))
p(HGNC:GSK3B) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph,Ser,33))
p(HGNC:GSK3B) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph,Ser,37))
p(HGNC:GSK3B) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph,Thr,41))

SET Evidence = "There was minimal S45 phosphorylation at baseline but increased K49
acetylation with HDAC6i was mirrored by increased S45 phosphorylation without any impact on
phosphorylation of S33/S37/T41 [103]."
p(HGNC:HDAC6) -| p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac,Lys,49))
p(HGNC:HDAC6) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph,Ser,45))
p(HGNC:HDAC6) cnc p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph,Ser,33))
p(HGNC:HDAC6) cnc p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph,Ser,37))
p(HGNC:HDAC6) cnc p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph,Thr,41))

SET Evidence = "K49 is a known site for ubiquitination, which primes-catenin for degradation by the
proteasome [110]."
p(HGNCGENEFAMILY:"Beta catenins",pmod(Ub,Lys,49)) -> deg(p(HGNCGENEFAMILY:"Beta catenins"))

SET Evidence = "In NPCs treated with MG-132, there was significant accumulation of
ubiquitinated beta-catenin, along with increase in total beta-catenin [103]."
#neural progenitor cells
#462382 - MG-132
a(PUBCHEM:462382) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ub,Lys,49))
a(PUBCHEM:462382) -> p(HGNCGENEFAMILY:"Beta catenins")

########How should i code?
SET Evidence = "However, in NPCs pre-treated
with the HDAC6 inhibitor ACY-1215, there was minimal change in ubiquitinated beta-catenin or total
beta-catenin in the presence of MG-132 [103]."
#NPC

SET Evidence = "Immunofluorescence experiments showed that that exposure
to ACY-1215 resulted in increasedbeta-catenin at the plasma membrane in human NPCs, where it
co-localized with N-cadherin [103]."
#human NPCs
SET Species = "9606"
a(PUBCHEM:53340666) -> complex(p(HGNCGENEFAMILY:"Beta catenins"),p(HGNC:CDH2),loc(GO:"plasma membrane"))
UNSET Species

SET Evidence = "Cell fractionation studies of NPCs treated with ACY-1215 showed
that the increase in Ac-K49-beta-catenin was in the membrane/cytoplasmic fraction and not in the
nuclear fraction."
a(PUBCHEM:53340666) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac,Lys,49),loc(GO:"plasma membrane"))
a(PUBCHEM:53340666) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac,Lys,49),loc(GO:cytoplasm))

SET Evidence = "HDAC6 knockdown in human NPCs also
led to increase in beta-catenin at the plasma membrane [103]."
#NPCs
SET Species = "9606"
p(HGNC:HDAC6) -| p(HGNCGENEFAMILY:"Beta catenins",loc(GO:"plasma membrane"))
UNSET Species

SET Evidence = "The beta-catenin/N-cadherin complex is important for cell-cell adhesion in the nervous
system and is present in both pre and postsynaptic neurons [88,100,116]."
SET MeSHAnatomy = "Nervous System"
complex(p(HGNCGENEFAMILY:"Beta catenins"),p(HGNC:CDH2)) -> bp(GO:"cell-cell adhesion")
UNSET MeSHAnatomy

SET Evidence = "Overexpression of beta-catenin in vivo in mice showed
increased dendritic growth and promoted neuronal activity [119]."
SET Species = "10090"
p(HGNCGENEFAMILY:"Beta catenins") -> bp(GO:"dendrite development")
p(HGNCGENEFAMILY:"Beta catenins") -> bp(GO:"neuronal signal transduction")
UNSET Species

SET Evidence = "In mice, ketamine induced inhibitory serine
phosphorylation of GSK3β, which was necessary for its antidepressant-like effects [120]."
SET Species = "10090"
a(CHEBI:ketamine) -> p(HGNC:GSK3B,pmod(Ph,Ser))
p(HGNC:GSK3B,pmod(Ph,Ser)) -| act(p(HGNC:GSK3B))
UNSET Species

SET Evidence = "The antidepressant-like effects of 5-HT2A
receptor antagonist ketanserin and the SSRI fluoxetine in rats were accompanied by increase in the
membrane fraction of β-catenin and a parallel increase in N-cadherin, but without any change in
levels of nuclear β-catenin [122]."
SET Species = "10116"
a(CHEBI:ketanserin) -| p(HGNC:HTR2A)
a(CHEBI:ketanserin) -> p(HGNCGENEFAMILY:"Beta catenins",loc(GO:"plasma membrane"))
a(CHEBI:ketanserin) -> p(HGNC:CDH2)
a(CHEBI:ketanserin) cnc p(HGNCGENEFAMILY:"Beta catenins",loc(GO:nucleus))
a(CHEBI:fluoxetine) -> p(HGNCGENEFAMILY:"Beta catenins",loc(GO:"plasma membrane"))
a(CHEBI:fluoxetine) -> p(HGNC:CDH2)
a(CHEBI:fluoxetine) cnc p(HGNCGENEFAMILY:"Beta catenins",loc(GO:nucleus))
UNSET Species

SET Evidence = "Beat-catenin links N-cadherin to the actin cytoskeleton and recruits intracellular partners to the
synaptic membrane to form co-complexes with N-cadherin [116]."
p(HGNCGENEFAMILY:"Beta catenins") -> complex(p(HGNC:CDH2),complex(GO:"actin cytoskeleton"))
p(HGNCGENEFAMILY:"Beta catenins") -> bp(GO:"synaptic vesicle membrane organization")

SET Evidence = "β-catenin regulates synaptic vesicle localization by recruiting synaptic proteins with
PDZ domains [116]."
p(HGNCGENEFAMILY:"Beta catenins") reg bp(GO:"synaptic vesicle localization")
complex(p(HGNCGENEFAMILY:"Beta catenins"),p(HGNC:CDH2)) -> p(HGNCGENEFAMILY:"PDZ domain containing")

SET Evidence = "These studies suggest a role for β-catenin in HDAC6i effects on
synaptogenesis through the interaction of acetylated β-catenin to PDZ-domain-containing synaptic proteins (Figure 2)."
#These studeis - mentioned above
p(HGNC:HDAC6) -- bp(GO:"synapse assembly")
a(PUBCHEM:53340666) -| p(HGNC:HDAC6)
p(HGNC:HDAC6) -| p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac))
a(PUBCHEM:53340666) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ac))

SET Evidence = "AKT knockdown also adversely impacts synaptogenesis in rodent hippocampal neurons, accompanied
by decreased dendritic spine density [133]."
SET Species = "10116"
SET MeSHAnatomy = "Hippocampus"
p(HGNC:AKT1) pos bp(GO:"synapse assembly")
p(HGNC:AKT1) -> bp(GO:"dendritic spine morphogenesis")
UNSET MeSHAnatomy
UNSET Species

SET Evidence = "Human neuronal cells treated with HDAC6i show increased
AKT acetylation, specifically at residues K163 and K377 in the kinase domain [128], which are distinct
from the PH-domain sites deacetylated by the class III KDACs SIRT1 and SIRT2 [134,135]."
SET Species = "9606"
SET Cell = "neuron"
p(HGNC:HDAC6) -| p(HGNC:AKT1,pmod(Ac,Lys,163))
p(HGNC:HDAC6) -| p(HGNC:AKT1,pmod(Ac,Lys,377))
UNSET Cell
UNSET Species

SET Evidence = "Treatment
with HDAC6i led to reduced binding of AKT to PIP3 and decreased its ability to phosphorylate
downstream targets including S552 onbeta-catenin that mediates its subcellular localization [128]."
p(HGNC:HDAC6) -| act(p(HGNC:AKT1),ma(GO:"phosphatidylinositol-3,4,5-trisphosphate binding"))
act(p(HGNC:AKT1),ma(GO:"phosphatidylinositol-3,4,5-trisphosphate binding")) -> p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph,Ser,552))
p(HGNCGENEFAMILY:"Beta catenins",pmod(Ph,Ser,552)) -> p(HGNCGENEFAMILY:"Beta catenins",loc(GO:"plasma membrane"))
